MedTrace Logo

Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes

NCT02282397 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2017-05-15

No results posted yet for this study

Summary

Evaluate if addition and use of real time continuous glucose monitoring (RT-CGM) improves glycemic outcome of patients using multiple daily injections (MDI) and self monitoring blood glucose (SMBG) testing, who are not at target glycemic control.

Conditions

Interventions

DEVICE

Continuous Glucose Monitor

RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.

Sponsors & Collaborators

  • Jaeb Center for Health Research

    collaborator OTHER

  • DexCom, Inc.

    lead INDUSTRY

Principal Investigators

  • David Price, MD · DexCom, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282397 on ClinicalTrials.gov